2004
DOI: 10.1016/j.ijgo.2004.05.017
|View full text |Cite
|
Sign up to set email alerts
|

Effects of finasteride on the morphology of polycystic ovaries

Abstract: Along with clinical and endocrine modifications, ovarian morphology continues to be the basis for the diagnosis of polycystic ovaries syndrome (PCOS) [1].Androgenic effects on the ovaries may be caused either by testosterone or by dihydrotestosterone. The enzyme that catalizes the transformation from testosterone to DHT is the 5-a-reductase, which is present in the follicles, stroma, and luteal bodies of women's ovaries.Treatment with inhibitors of the 5-a-reductase blocks the transformation from testosterone … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2019
2019
2019
2019

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 3 publications
(4 reference statements)
0
3
0
Order By: Relevance
“…In a population study in 2004, 31 PCOS women were given oral finasteride or the same dose of placebo. The experiment concluded that the PCOS women who took finasteride did not show a significant difference in ovarian capacity compared with the control group [33]. In our study, the PCOS rats in the P-FEx group showed a significant reduction in the area of the corpus luteum.…”
Section: Discussionmentioning
confidence: 41%
“…In a population study in 2004, 31 PCOS women were given oral finasteride or the same dose of placebo. The experiment concluded that the PCOS women who took finasteride did not show a significant difference in ovarian capacity compared with the control group [33]. In our study, the PCOS rats in the P-FEx group showed a significant reduction in the area of the corpus luteum.…”
Section: Discussionmentioning
confidence: 41%
“…In a double‐blind RCT, administration of finasteride with recombinant FSH (rFSH) during ovarian stimulation improved the ovulation rate in hyperandrogenic anovulatory women with PCOS and prior resistance to gonadotropin stimulation . Another RCT used ultrasound‐guided assessment to demonstrate no differences in volume and number of cysts in ovaries of women treated with finasteride (5 mg/day) after 3 months …”
Section: Resultsmentioning
confidence: 99%
“…71 Another RCT used ultrasound-guided assessment to demonstrate no differences in volume and number of cysts in ovaries of women treated with finasteride (5 mg/day) after 3 months. 72 Hidradenitis suppurativa A couple case series examined finasteride (5 mg/day) for hidradenitis suppurativa (HS) therapy. 42,[73][74][75][76] Five women and two men with HS unresponsive to antibiotics were treated with finasteride.…”
Section: Acnementioning
confidence: 99%